Pediatric multisystem inflammatory syndrome associated with COVID-19: urgent attention required

Area of Science:

• Pediatrics
• Infectious Diseases
• Immunology

Background:

• Multisystemic inflammatory syndrome (MIS) is a severe manifestation of coronavirus disease 2019 (COVID-19) in pediatric populations.
• While most children experience mild COVID-19, a subset develops a hyperinflammatory response.

Purpose of the Study:

• To define the epidemiological and clinical features of MIS associated with SARS-CoV-2 infection in children and adolescents.
• To aid healthcare professionals in recognizing and differentiating MIS from other pediatric conditions.

Main Methods:

• A comprehensive literature review was conducted.
• Articles published in 2020 were systematically searched across PubMed, Medline, Scopus, SciELO, and Cochrane databases.

Main Results:

• MIS is linked to prior SARS-CoV-2 exposure and presents as a serious clinical disorder.
• Key clinical signs include shock, elevated inflammatory markers, fever, rash, conjunctivitis, edema, extremity pain, and gastrointestinal issues.
• The presentation can resemble Kawasaki disease or toxic shock syndrome.

Conclusions:

• MIS represents a significant, albeit less common, severe outcome of COVID-19 in the pediatric population.
• Early identification and appropriate management are crucial for improving outcomes.
• Healthcare providers need updated information to accurately diagnose MIS and initiate timely treatment.